Given the multiple mechanisms through which CCL28 can enhance tumor development by attracting plasma cells, Tregs, and myofibroblast-like stromal cells to the tumor site, and the numerous studies reporting the anti-tumor benefits of its downregulation, CCL28 is a promising therapeutic target whose inhibition could have significant implications on cancer patient survival [7]. Here, CCL28 is linked to cancer.